Home » Stocks » Surface Oncology

Surface Oncology, Inc. (SURF)

Stock Price: $6.30 USD -0.23 (-3.52%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 178.43M
Revenue (ttm) 39.52M
Net Income (ttm) -28.02M
Shares Out 28.32M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $6.30
Previous Close $6.53
Change ($) -0.23
Change (%) -3.52%
Day's Open 6.60
Day's Range 6.20 - 6.65
Day's Volume 450,058
52-Week Range 1.15 - 7.66

More Stats

Market Cap 178.43M
Enterprise Value 127.02M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.32M
Float 2.14M
EPS (basic) -1.02
EPS (diluted) -1.01
FCF / Share -2.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 720,600
Short Ratio 0.12
Short % of Float 4.29%
Beta 2.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.52
PB Ratio 1.52
Revenue 39.52M
Operating Income -29.88M
Net Income -28.02M
Free Cash Flow -58.09M
Net Cash 51.41M
Net Cash / Share 1.82
Gross Margin -93.02%
Operating Margin -75.61%
Profit Margin -70.90%
FCF Margin -147.00%
ROA -11.88%
ROE -30.80%
ROIC -26.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(63.97% upside)
Current: 6.30
Target: 10.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-74.15%363.25%93.4%-
Gross Profit15.3659.4212.836.63
Operating Income-57.37-9.15-45.99-18.00
Net Income-54.79-6.60-45.38-17.45
Shares Outstanding27.8519.992.472.39
Earnings Per Share-1.97-0.33-18.35-7.31
Operating Cash Flow-60.14-13.22-12.4241.41
Capital Expenditures-1.54-2.02-1.97-0.84
Free Cash Flow-61.68-15.24-14.4040.58
Cash & Equivalents10716064.3980.24
Total Debt25.04---
Net Cash / Debt81.7216064.3980.24
Book Value56.67103-67.31-26.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Surface Oncology, Inc.
Country United States
Employees 49
CEO J. Jeffrey Goater

Stock Information

Ticker Symbol SURF
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SURF
IPO Date April 19, 2018


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDAÂ (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.